FDA Public Hearing Today on Potential CBD Regulation

The agency is hosting a public hearing on May 31 to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including cannabidiol.

The Food and Drug Administration is hosting a public hearing on May 31 to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including cannabidiol. The public hearing will be held from 8 a.m. to 6 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, in Silver Spring, Md.

FDA had announced the hearing on April 2, saying it would also accept electronic or written comments until July 2, 2019. Visit www.regulations.gov and search for docket number FDA-2019-N-1482 to file a comment.

The agency also formed an internal agency working group to explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed, including consideration of what statutory or regulatory changes might be needed and what the public health impact of that marketing would be.

comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - October 2019

    October 2019

    Featuring:

    • WINTER HAZARDS
      Preparing for Old Man Winter's Arrival
    • CONSTRUCTION
      Staying Safe in the Trenches
    • INDUSTRIAL HYGIENE
      Setting a Higher Standard: The Limitations of Regulatory Limits
    • ELECTRICAL SAFETY
      Five Important Things to Know About Arc Flash PPE Programs
    View This Issue